A Phase II Open-label Multicenter Exploratory Study to Assess Efficacy of Pembrolizumab Re-challenge as Second or Further Line in Patients With Advanced Non - Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Nov 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms Replay
- 07 Aug 2018 Status changed from not yet recruiting to recruiting.
- 04 Jun 2018 Planned End Date changed from 15 Jun 2023 to 15 Jul 2023.
- 04 Jun 2018 Planned primary completion date changed from 15 Jun 2022 to 15 Jul 2022.